ER-100: A Partial Epigenetic Reprogramming Therapy Enters Human Testing
Life Biosciences has dosed the first patient in a Phase 1 clinical trial for ER-100, an investigational gene therapy for optic neuropathies. The trial, registered as NCT07290244, will assess the safety and tolerability of this approach, which uses three Yamanaka factors to reset cellular gene expression patterns.
















































